Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.

Werfel TA, Wang S, Jackson MA, Kavanaugh TE, Joly MM, Lee LH, Hicks DJ, Sanchez V, Ericsson PG, Kilchrist KV, Dimobi SC, Sarett SM, Brantley-Sieders DM, Cook RS, Duvall CL.

Cancer Res. 2018 Apr 1;78(7):1845-1858. doi: 10.1158/0008-5472.CAN-17-2388. Epub 2018 Jan 22.

2.

The receptor tyrosine kinase EphA2 promotes glutamine metabolism in tumors by activating the transcriptional coactivators YAP and TAZ.

Edwards DN, Ngwa VM, Wang S, Shiuan E, Brantley-Sieders DM, Kim LC, Reynolds AB, Chen J.

Sci Signal. 2017 Dec 5;10(508). pii: eaan4667. doi: 10.1126/scisignal.aan4667.

3.

Lipophilic siRNA targets albumin in situ and promotes bioavailability, tumor penetration, and carrier-free gene silencing.

Sarett SM, Werfel TA, Lee L, Jackson MA, Kilchrist KV, Brantley-Sieders D, Duvall CL.

Proc Natl Acad Sci U S A. 2017 Aug 8;114(32):E6490-E6497. doi: 10.1073/pnas.1621240114. Epub 2017 Jul 24.

4.

Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.

Morrison Joly M, Williams MM, Hicks DJ, Jones B, Sanchez V, Young CD, Sarbassov DD, Muller WJ, Brantley-Sieders D, Cook RS.

Breast Cancer Res. 2017 Jun 30;19(1):74. doi: 10.1186/s13058-017-0868-8.

5.

Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.

Song W, Hwang Y, Youngblood VM, Cook RS, Balko JM, Chen J, Brantley-Sieders DM.

Oncogene. 2017 Oct 5;36(40):5620-5630. doi: 10.1038/onc.2017.170. Epub 2017 Jun 5.

6.

LIM-Only Protein 4 (LMO4) and LIM Domain Binding Protein 1 (LDB1) Promote Growth and Metastasis of Human Head and Neck Cancer (LMO4 and LDB1 in Head and Neck Cancer).

Simonik EA, Cai Y, Kimmelshue KN, Brantley-Sieders DM, Loomans HA, Andl CD, Westlake GM, Youngblood VM, Chen J, Yarbrough WG, Brown BT, Nagarajan L, Brandt SJ.

PLoS One. 2016 Oct 25;11(10):e0164804. doi: 10.1371/journal.pone.0164804. eCollection 2016.

7.

Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers.

Morrison Joly M, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov dos D, Muller WJ, Brantley-Sieders D, Cook RS.

Cancer Res. 2016 Aug 15;76(16):4752-64. doi: 10.1158/0008-5472.CAN-15-3393. Epub 2016 Apr 25.

8.

Determination of the CD148-Interacting Region in Thrombospondin-1.

Takahashi K, Sumarriva K, Kim R, Jiang R, Brantley-Sieders DM, Chen J, Mernaugh RL, Takahashi T.

PLoS One. 2016 May 5;11(5):e0154916. doi: 10.1371/journal.pone.0154916. eCollection 2016.

9.

The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer.

Youngblood VM, Kim LC, Edwards DN, Hwang Y, Santapuram PR, Stirdivant SM, Lu P, Ye F, Brantley-Sieders DM, Chen J.

Cancer Res. 2016 Apr 1;76(7):1825-36. doi: 10.1158/0008-5472.CAN-15-0847. Epub 2016 Feb 1.

10.

mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis.

Morrison MM, Young CD, Wang S, Sobolik T, Sanchez VM, Hicks DJ, Cook RS, Brantley-Sieders DM.

PLoS Genet. 2015 Jul 1;11(7):e1005291. doi: 10.1371/journal.pgen.1005291. eCollection 2015 Jul.

11.

Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer.

Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, Levin M, Horiates M, Palma NA, Wang K, Stephens PJ, Perou CM, Weaver AM, O'Shaughnessy JA, Chang JC, Park BH, Liebler DC, Cook RS, Arteaga CL.

Mol Cell Proteomics. 2015 Jul;14(7):1959-76. doi: 10.1074/mcp.M115.049783. Epub 2015 May 7.

12.

The CCL2 chemokine is a negative regulator of autophagy and necrosis in luminal B breast cancer cells.

Fang WB, Yao M, Jokar I, Alhakamy N, Berkland C, Chen J, Brantley-Sieders D, Cheng N.

Breast Cancer Res Treat. 2015 Apr;150(2):309-20. doi: 10.1007/s10549-015-3324-4. Epub 2015 Mar 6.

13.

Regulation of endothelial cell proliferation and vascular assembly through distinct mTORC2 signaling pathways.

Wang S, Amato KR, Song W, Youngblood V, Lee K, Boothby M, Brantley-Sieders DM, Chen J.

Mol Cell Biol. 2015 Apr;35(7):1299-313. doi: 10.1128/MCB.00306-14. Epub 2015 Jan 12.

14.

Elevated Slit2 Activity Impairs VEGF-Induced Angiogenesis and Tumor Neovascularization in EphA2-Deficient Endothelium.

Youngblood V, Wang S, Song W, Walter D, Hwang Y, Chen J, Brantley-Sieders DM.

Mol Cancer Res. 2015 Mar;13(3):524-37. doi: 10.1158/1541-7786.MCR-14-0142. Epub 2014 Dec 12.

15.

Efferocytosis produces a prometastatic landscape during postpartum mammary gland involution.

Stanford JC, Young C, Hicks D, Owens P, Williams A, Vaught DB, Morrison MM, Lim J, Williams M, Brantley-Sieders DM, Balko JM, Tonetti D, Earp HS 3rd, Cook RS.

J Clin Invest. 2014 Nov;124(11):4737-52. doi: 10.1172/JCI76375. Epub 2014 Sep 24.

16.

Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC.

Amato KR, Wang S, Hastings AK, Youngblood VM, Santapuram PR, Chen H, Cates JM, Colvin DC, Ye F, Brantley-Sieders DM, Cook RS, Tan L, Gray NS, Chen J.

J Clin Invest. 2014 May;124(5):2037-49. doi: 10.1172/JCI72522. Epub 2014 Apr 8.

17.

JNK signaling mediates EPHA2-dependent tumor cell proliferation, motility, and cancer stem cell-like properties in non-small cell lung cancer.

Song W, Ma Y, Wang J, Brantley-Sieders D, Chen J.

Cancer Res. 2014 May 1;74(9):2444-54. doi: 10.1158/0008-5472.CAN-13-2136. Epub 2014 Mar 7.

18.

VAMP-associated protein B (VAPB) promotes breast tumor growth by modulation of Akt activity.

Rao M, Song W, Jiang A, Shyr Y, Lev S, Greenstein D, Brantley-Sieders D, Chen J.

PLoS One. 2012;7(10):e46281. doi: 10.1371/journal.pone.0046281. Epub 2012 Oct 1.

19.

Local breast cancer spatial patterning: a tool for community health resource allocation to address local disparities in breast cancer mortality.

Brantley-Sieders DM, Fan KH, Deming-Halverson SL, Shyr Y, Cook RS.

PLoS One. 2012;7(9):e45238. doi: 10.1371/journal.pone.0045238. Epub 2012 Sep 28.

20.

Effects of cancer-associated EPHA3 mutations on lung cancer.

Zhuang G, Song W, Amato K, Hwang Y, Lee K, Boothby M, Ye F, Guo Y, Shyr Y, Lin L, Carbone DP, Brantley-Sieders DM, Chen J.

J Natl Cancer Inst. 2012 Aug 8;104(15):1182-97. doi: 10.1093/jnci/djs297. Epub 2012 Jul 24.

21.

Clinical relevance of Ephs and ephrins in cancer: lessons from breast, colorectal, and lung cancer profiling.

Brantley-Sieders DM.

Semin Cell Dev Biol. 2012 Feb;23(1):102-8. doi: 10.1016/j.semcdb.2011.10.014. Epub 2011 Oct 21. Review.

22.

Eph/ephrin profiling in human breast cancer reveals significant associations between expression level and clinical outcome.

Brantley-Sieders DM, Jiang A, Sarma K, Badu-Nkansah A, Walter DL, Shyr Y, Chen J.

PLoS One. 2011;6(9):e24426. doi: 10.1371/journal.pone.0024426. Epub 2011 Sep 15.

23.

Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium.

Brantley-Sieders DM, Dunaway CM, Rao M, Short S, Hwang Y, Gao Y, Li D, Jiang A, Shyr Y, Wu JY, Chen J.

Cancer Res. 2011 Feb 1;71(3):976-87. doi: 10.1158/0008-5472.CAN-10-3396. Epub 2010 Dec 8.

24.

Cooperative signaling between Slit2 and Ephrin-A1 regulates a balance between angiogenesis and angiostasis.

Dunaway CM, Hwang Y, Lindsley CW, Cook RS, Wu JY, Boothby M, Chen J, Brantley-Sieders DM.

Mol Cell Biol. 2011 Feb;31(3):404-16. doi: 10.1128/MCB.00667-10. Epub 2010 Dec 6.

25.

Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy.

Zhuang G, Brantley-Sieders DM, Vaught D, Yu J, Xie L, Wells S, Jackson D, Muraoka-Cook R, Arteaga C, Chen J.

Cancer Res. 2010 Jan 1;70(1):299-308. doi: 10.1158/0008-5472.CAN-09-1845. Epub 2009 Dec 22.

26.

Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo.

Brantley-Sieders DM, Zhuang G, Vaught D, Freeman T, Hwang Y, Hicks D, Chen J.

Mol Cancer Res. 2009 May;7(5):615-23. doi: 10.1158/1541-7786.MCR-08-0401. Epub 2009 May 12.

27.

Regulation of mammary gland branching morphogenesis by EphA2 receptor tyrosine kinase.

Vaught D, Chen J, Brantley-Sieders DM.

Mol Biol Cell. 2009 May;20(10):2572-81. doi: 10.1091/mbc.E08-04-0378. Epub 2009 Mar 25.

28.

Eph receptors in breast cancer: roles in tumor promotion and tumor suppression.

Vaught D, Brantley-Sieders DM, Chen J.

Breast Cancer Res. 2008;10(6):217. doi: 10.1186/bcr2207. Epub 2008 Dec 22. Review.

29.

Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site.

Li B, Vincent A, Cates J, Brantley-Sieders DM, Polk DB, Young PP.

Cancer Res. 2009 Jan 1;69(1):338-48. doi: 10.1158/0008-5472.CAN-08-1565.

30.

Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase.

Fang WB, Brantley-Sieders DM, Hwang Y, Ham AJ, Chen J.

J Biol Chem. 2008 Jun 6;283(23):16017-26. doi: 10.1074/jbc.M709934200. Epub 2008 Apr 3.

31.

The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling.

Brantley-Sieders DM, Zhuang G, Hicks D, Fang WB, Hwang Y, Cates JM, Coffman K, Jackson D, Bruckheimer E, Muraoka-Cook RS, Chen J.

J Clin Invest. 2008 Jan;118(1):64-78.

32.
33.

Expression of the TAL1/SCL transcription factor in physiological and pathological vascular processes.

Tang T, Shi Y, Opalenik SR, Brantley-Sieders DM, Chen J, Davidson JM, Brandt SJ.

J Pathol. 2006 Sep;210(1):121-9.

PMID:
16841371
34.

Essential role of Vav family guanine nucleotide exchange factors in EphA receptor-mediated angiogenesis.

Hunter SG, Zhuang G, Brantley-Sieders D, Swat W, Cowan CW, Chen J.

Mol Cell Biol. 2006 Jul;26(13):4830-42.

35.

Inhibition of retinal neovascularization by soluble EphA2 receptor.

Chen J, Hicks D, Brantley-Sieders D, Cheng N, McCollum GW, Qi-Werdich X, Penn J.

Exp Eye Res. 2006 Apr;82(4):664-73. Epub 2005 Dec 15.

PMID:
16359662
36.

Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression.

Brantley-Sieders DM, Fang WB, Hicks DJ, Zhuang G, Shyr Y, Chen J.

FASEB J. 2005 Nov;19(13):1884-6. Epub 2005 Sep 15.

PMID:
16166198
37.

A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis.

Fang WB, Brantley-Sieders DM, Parker MA, Reith AD, Chen J.

Oncogene. 2005 Nov 24;24(53):7859-68.

PMID:
16103880
38.

Eph receptor tyrosine kinases in tumor and tumor microenvironment.

Brantley-Sieders D, Schmidt S, Parker M, Chen J.

Curr Pharm Des. 2004;10(27):3431-42. Review.

PMID:
15544526
39.

Eph receptor tyrosine kinases in angiogenesis: from development to disease.

Brantley-Sieders DM, Chen J.

Angiogenesis. 2004;7(1):17-28. Review.

PMID:
15302992
40.

EphA2 receptor tyrosine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation.

Brantley-Sieders DM, Caughron J, Hicks D, Pozzi A, Ruiz JC, Chen J.

J Cell Sci. 2004 Apr 15;117(Pt 10):2037-49. Epub 2004 Mar 30.

41.

Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor beta1.

Muraoka RS, Koh Y, Roebuck LR, Sanders ME, Brantley-Sieders D, Gorska AE, Moses HL, Arteaga CL.

Mol Cell Biol. 2003 Dec;23(23):8691-703.

Supplemental Content

Loading ...
Support Center